The urologic oncology fellowship is supported by the University of Utah Urology together with the Huntsman Cancer Institute. The fellowship focuses on the management of complex genitourinary cancers. Core faculty include Drs. Christopher Dechet, Brock O’Neil, and Alejandro Sanchez. As the only NCI-designated cancer center in the intermountain west, the clinically focused program includes a wide breadth of urologic cancers. Training encompasses a high-volume of established and novel techniques including:
- Robotic prostatectomy
- Robotic and open partial nephrectomy, including retroperitoneal approaches
- Robotic cystectomy, including intracorporeal urinary diversion (conduit, neobladder)
- Open cystectomy and urinary diversion (conduit, neobladder)
- Open nephrectomy with caval thrombectomy
- Laparoscopic nephrectomy
- Robotic, laparoscopic and open adrenalectomy
- Post-chemotherapy retroperitoneal lymphadenectomy, including extraperitoneal approaches
- Endoscopic bladder cancer procedures, including blue light cystoscopy
- Focal therapy for prostate cancer
- Transperineal and Transrectal MRI-guided prostate biopsy
- Multidisciplinary management of urologic cancers together with dedicated urologic medical oncology, radiology, radiation oncology, and pathology.
- Participation in our high-risk prostate cancer and Von Hippel Lindau/High-risk kidney cancer clinics in conjunction with genetic counselors.
Fellowship positions: One per year
Duration: One year, Flexible start from July 1st August 1st
Location: Huntsman Cancer Institute and University of Utah in Salt Lake City, Utah
Salary & Benefits
The salary for is based upon the current salary for the fellow’s corresponding post-graduate year. We would expect this would be a PGY 6 or PGY 7 salary. The fellowship includes retirement benefits, up to 27% of salary, which is contributed into retirement accounts separate from any 403 or 457 retirement. Health benefits are excellent. Family leave follows a well-established policy in the Department of Surgery.
During the course of the fellowship, ample research opportunities are available based on the fellow’s research interests. Fellows will be provided with protected academic time to pursue research and other educational activities. The urologic oncology research group has robust resources to support clinical and health services research projects, clinical trial development and support, and growing collaborations in translational cancer research.
We anticipate that the fellow will participate in 2-3 professional society meetings each year with travel costs covered by the division. It is anticipated that fellows will attend the annual meeting of the Society of Urologic Oncology. Participating in other professional meetings depends upon the fellow’s interests and opportunities.